TY  - GEN
AU  - Earl,H M
AU  - Hiller,L
AU  - Dunn,J A
AU  - Vallier,A-L
AU  - Bowden,S J
AU  - Jordan,S D
AU  - Blows,F
AU  - Munro,A
AU  - Bathers,S
AU  - Grieve,R
AU  - Spooner,D A
AU  - Agrawal,R
AU  - Fernando,I
AU  - Brunt,A M
AU  - O'Reilly,S M
AU  - Crawford,S M
AU  - Rea,D W
AU  - Simmonds,P
AU  - Mansi,J L
AU  - Stanley,A
AU  - McAdam,K
AU  - Foster,L
AU  - Leonard,R C F
AU  - Twelves,C J
AU  - Cameron,D
AU  - Bartlett,J M S
AU  - Pharoah,P
AU  - Provenzano,E
AU  - Caldas,C
AU  - Poole,C J
TI  - Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
SN  - 1532-1827
PY  - 2012///1211
KW  - Aged
KW  - Antibiotics, Antineoplastic
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Chemotherapy, Adjuvant
KW  - Cyclophosphamide
KW  - Epirubicin
KW  - Female
KW  - Fluorouracil
KW  - Follow-Up Studies
KW  - Humans
KW  - Medication Adherence
KW  - Methotrexate
KW  - Middle Aged
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1038/bjc.2012.370
ER  -